Saturday, October 24, 2015

07:00-08:30
Session 11: Industry Breakfast Symposium                                                                                     Hall A

IORT for early breast cancer: From clinical trials to clinical reality
Supported by ZEISS
 

Session not included in main CME/CPD program 
08:30-10:00
Session 12: Controversies in adjuvant endocrine therapy                                                          Hall A
Chairpersons

Eva Segelov, Australia
Arlene Chan, Australia

08:30

Fertility preservation in 2015
Kate Stern , Australia

09:00-09:30
Debate: That all patients with hormone receptor positive breast cancer should have 10 years of endocrine therapy
Yes: Louis Chow, Hong Kong
No: Nicole McCarthy, Australia 
Discussion
09:30

The SOFT/TEXT results: How these have changed my practice
Prue Francis, Australia
10:00-10:30

Coffee break and poster viewing

10:30-11:30
Session 13: Controversies in brain metastases                                                                              Hall A
Chairpersons

Nicholas Wilcken, Australia
Abram Recht, USA
10:30-11:10
Difficult cases in the local management of low volume CNS metastasis
Kate Drummond, Australia
Claire Phillips, Australia
 
11:10 Systemic management of CNS-only HER2-positive metastatic disease
Edith A. Perez, USA
 
10:30-11:30
Session 14: Controversies in DCIS: Should all cases be treated?                                           Hall B
Chairpersons

John Collins, Australia
Shu Wang, China

10:30 Clinical implications of DCIS subtypes
Gelarah Farshid , Australia
10:40 The Sloane Project: What can we learn from a 12,000 patient prospective cohort study of DCIS?
Alastair Thompson , USA
10:50-11:30
Debate: Point and counterpoint
The screening debate risks undertreatment of DCIS
John Boyages, Australia
Overdiagnosis and overtreatment is a major problem with DCIS
Laura Esserman, USA
Discussion
 
11:30-13:00
Session 15: Industry Symposium                                                                                                        Hall A

Management of endocrine resistance
Supported by Novartis Oncology
 

Session not included in main CME/CPD program

11:30-13:00
Session 16: Who is responsible for follow-up                                                                                 Hall B
and survivorship care of women with early stage breast cancer?
Chairpersons

Michael Jefford , Australia
Christine Nolan, CEO of BCNA, Australia
11:30-12:15
Debate: That women with early stage breast cancer require routine hospital/specialist follow up after finishing initial treatments
Yes: Fran Boyle, Australia
No: Jon Emery, Australia 
Discussion
 
12:15-13:00
Survivorship care planning: Is it for everyone?
Setting the scene
Michael Jefford, Australia

Panel discussion
Judy Evans, Australia
Kerry Shanahan, Australia
Fran Boyle, Australia
Jon Emery, Australia
Kym Berchtenbreiter, Australia
  
13:00-14:30 Lunch break and poster viewing
13:30-14:20
Case Discussion Panel                                                                                                                        Hall A
Chairpersons
David Speakman, Australia
Susan Pendlebury, Australia
 

Participants:     

Stephen R.D. Johnston, UK
Eva Segelov, Australia
Alastair Thompson, USA
Louis Chow, Hong Kong
Abram Recht, USA          
Lisa Sheeran, Australia
Jane Fox, Australia
14:30-15:30
Session 17: Controversies in breast reconstruction                                                                      Hall A
Chairpersons

Jane Fox, Australia
Mario Guerrieri, Australia
14:30-15:15
Debate: Breast reconstruction and radiation therapy: Uncomfortable bed-fellows or compatible partners?

Radiotherapy and reconstruction: What is the evidence?
John Boyages, Australia

That reconstruction should be delayed if PMRT is needed
James Kollias, Australia

That immediate reconstruction is feasible despite PMRT
Hamish Farrow, Australia

Discussion
 
15:15 Without PROs, you cannot assess your outcomes after mastectomy
Elisabeth Elder, Australia
14:30-15:30
Session 18: Controversies in advanced breast cancer                                              Hall B
Chairpersons

Stephen R.D. Johnston, UK
Catherine Oakman, Australia 
14:30-15:00
Debate: That oligometastatic disease on staging should change locoregional management
Yes: Claire Phillips, Australia
No: Bruce Mann, Australia
Discussion
 
15:00-15:30
Debate: That the palliative mindset for low volume metastatic breast cancer is now redundant
Yes: Richard De Boer, Australia
No: Michael Green, Australia
Discussion
 
15:35-16:50
Session 19: Breast cancer 2020                                                                                                      Hall A
Chairpersons

Bruce Mann, Australia
Richard De Boer, Australia
15:35
Will immunotherapy change the paradigm for breast cancer therapy? 
Sherene Loi, Australia
15:55
Replacing tissue biopsies with liquid biopsies: The future is written in blood
Sarah-Jane Dawson, Australia
16:15
What will change breast cancer management in the next 5 years?
Javier Cortes, Spain
16:50-17:00
Congress closing and award presentation                                                                                      Hall A
 
Richard De Boer, Australia
Javier Cortes, Spain
Bruce Mann, Australia